Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal paclitaxel plus anlotinib for previously treated small cell lung cancer
ChiCTR1900021983Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2019
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liposomal paclitaxel and anlotinib in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoints: objective response rate and progression-free survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
liposomal paclitaxelanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1900021983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021983.